Skip to content

From the body to the mind: interoception and sense of agency as mechanisms of depression reduction in the Body-Mind Axial Awareness (BMAA).

Yunn-Wen Lien, Shan-Chuan Teng, Li-Yun Wei

Frontiers in Psychology April 7, 2026 DOI: 10.3389/fpsyg.2026.1755698 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Pre-post design with an active control group Peer reviewed
Sample size 71
Population University students
Intervention Body-Mind Axial Awareness (BMAA) method
Duration 10-week course
Measures Beck Depression Inventory, Multidimensional Assessment of Interoceptive Awareness (MAIA), Sense of Agency Scale
Topics Depression Meditation
Keywords Emotion regulation Wellbeing Sense of agency Interoception Embodied practices
Key points A 10-week BMAA course was associated with significant reductions in depressive tendencies, improvements across all interoceptive sensibility dimensions, and decreases in negative sense of agency relative to an active control group. Mediation analyses indicated that improvements in Not-Distracting, Attention Regulation, and Trusting interoception led to reduced negative sense of agency, which in turn contributed to lower depressive tendencies; the authors argue this is the first evidence that interoception and sense of agency play sequential roles in how embodied practices support emotion regulation.

Abstract

Introduction: Psychological wellbeing among young adults has declined globally, along with rising levels of depression, creating an educational and societal crisis and highlighting the urgent need for school-based mental health interventions. In response, the Body-Mind Axial Awareness (BMAA) method-an embodied body-mind enhancement program rooted in East Asian self-cultivation traditions-was developed at National Taiwan University to promote students' mental resilience and wellbeing.

Methods: This study examined the effects and mechanisms of a 10-week BMAA course on depressive tendencies (measured by the Beck Depression Inventory), interoceptive sensibility [measured by the Multidimensional Assessment of Interoceptive Awareness (MAIA)], and sense of agency (measured by the Sense of Agency Scale) in university students. To test these aims, a pre-post design with an active control group was used (BMAA: n = 50; control: n = 21).

Results: The findings showed that BMAA participants experienced significant reductions in depressive tendencies, improvements across all dimensions of interoceptive sensibility, and decreases in negative sense of agency (SoNA) compared with the control group. Mediation analyses further revealed a serial pathway in which enhancements in the Not-Distracting, Attention Regulation, and Trusting dimension of interoception led to reductions in SoNA, which in turn contributed to decreased depressive tendencies. Additionally, independent mediation pathways involving the Not-Worrying dimension and SoNA alone were also significant.

Discussion: To our knowledge, this is the first evidence that interoception and the sense of agency play crucial, sequential roles in how embodied practices like 2 BMAA support emotion regulation. BMAA not only offers a feasible method for promoting students' mental health and resilience but also shows promising potential for broader clinical use in the future.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Explore topics